Experimental combo shows promise for Tough-to-Treat leukemia
NCT ID NCT02005289
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of two drugs—MOR00208 (an antibody that targets cancer cells) and lenalidomide (which boosts the immune system)—in 41 people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic leukemia (PLL). Some participants had not been treated before, while others had relapsed or not responded to prior therapies, including ibrutinib. The goal was to see how many patients achieved a significant reduction in cancer. The study also included a small pilot group with Richter's transformation, a more aggressive form of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MOR00208 (a monoclonal antibody) and lenalidomide (an immune-modulating drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with hard-to-treat CLL, SLL, or PLL, including those who have stopped responding to other therapies.
- What could go wrong
- This is a small, early-phase study (41 participants) with no control group, so results may not apply broadly. Side effects from the combination are possible, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outsmart resistant lymphomas?
- Engineered immune cells take on tough lymphomas
- New transplant recipe aims to tame Graft-Versus-Host disease
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- Engineered immune cells take on tough blood cancers in early trial